CRPC-001
Castration-Resistant Prostate Cancer · AR/PTEN/BRCA Engine · VIZASL v1
MEBICAL · EOSE Fleet · Day 95 · Real data · Cited · γ₁-anchored
MEBICAL · URO-ONCOLOGY← RESEARCH
Castration-Resistant Prostate Cancer
γ₁ floor anchor
PHASES
SORRIES
BM
NPs
Molecular Engine + Treatment
Enzalutamide/Abiraterone mCRPC PROVEN
2nd-gen AR pathway inhibitors. OS 34.7-36.5mo.
Beer 2014 NEJM PREVAIL
Olaparib PROfound BRCA/HRR PROVEN
BRCA1/2 or HRR. PFS 7.4 vs 3.6mo. FDA 2020.
de Bono 2020 NEJM
Lu-177 PSMA VISION PROVEN
PSMA+ mCRPC. OS 15.3 vs 11.3mo. FDA 2022.
Sartor 2021 NEJM VISION
Docetaxel CHAARTED PROVEN
mHSPC. OS 57.6 vs 44.0mo upfront docetaxel.
Sweeney 2015 NEJM
Lu-177+Olaparib SyNERGY OPEN
PSMA + PARP inhibition combo. Phase II ongoing.
NCT04419402
Open Sorries — Click to Expand
S-1 SORRY-1 · AR-V7 Testing Not Standardized
S-2 SORRY-2 · PSMA Expression Heterogeneity
S-3 SORRY-3 · Neuroendocrine Transformation
S-4 SORRY-4 · Bone Met Pain Management
S-5 SORRY-5 · De Novo CRPC Sequencing
Biomarkers + Signal
See Phases tab for molecular classification details. Key biomarkers noted in phase gates above.
Novel Patterns
Emerging therapies and patterns logged in PEMCLAU v11. See GREYBACK yang case corpus for yin/yang attack-defense mapping.
CRPC-001 · AR-V7 RESISTANCE · Lu-177 PSMA VISION · γ₁ = 14.134725141734693
γ₁ = 14.134725141734693